Nivolumab and its use in the second-line treatment of metastatic urothelial cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Nivolumab is a fully human monoclonal antibody blocking PD-1 with demonstrated effectiveness against metastatic urothelial carcinoma. In this review, we describe the pharmacological properties of nivolumab and the treatment of metastatic urothelial carcinoma with this checkpoint inhibitor after the failure of first-line platinum-based chemotherapy. Cancer immunotherapy by checkpoint inhibition offers potential to prolong patient survival with well manageable toxicity although serious immune-related adverse events may occur. The overall response rate to nivolumab after first-line chemotherapy is about 20%. Patients unfit for cisplatin may benefit from first-line cancer immunotherapy. It remains unclear which patient will respond and PD-1/PD-L1 expression alone is not a sufficiently reliable predictive biomarker.

Original languageEnglish
Pages (from-to)2683-2690
Number of pages8
JournalFuture Oncology
Volume14
Issue number26
DOIs
Publication statusPublished - Nov 2018

Fingerprint Dive into the research topics of 'Nivolumab and its use in the second-line treatment of metastatic urothelial cancer'. Together they form a unique fingerprint.

Cite this